- Home
- PSTL vs FBRX Comparison
PSTL vs FBRX Comparison
Compare PSTL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTL | FBRX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.8M | 367.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSTL | FBRX |
|---|---|---|
| Price | $16.09 | $27.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $17.58 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 215.9K | 154.4K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | ★ 508.95 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $91,195,000.00 | N/A |
| Revenue This Year | $25.13 | N/A |
| Revenue Next Year | $13.50 | N/A |
| P/E Ratio | $33.01 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $12.26 | $4.90 |
| 52 Week High | $16.50 | $31.27 |
Technical Indicators
Market Signals| Indicator | PSTL | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 69.76 |
| Support Level | $15.76 | $26.35 |
| Resistance Level | $16.41 | $31.27 |
| Average True Range (ATR) | 0.30 | 2.85 |
| MACD | 0.06 | 0.38 |
| Stochastic Oscillator | 79.86 | 75.04 |
Price Performance
Historical ComparisonAbout PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).